Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M

Kiniksa Pharmaceuticals International, plc

2025-Q1 EPS reported $0.11 revenue$137,785,000

ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.
Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.
KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.
Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.
Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.